GRCE Grace Therapeutics, Inc.
Price Chart
Executive Summary
Grace Therapeutics announced that results from its STRIVE-ON Phase 3 safety trial for GTx-104, an IV formulation of nimodipine for aneurysmal subarachnoid hemorrhage (aSAH), will be presented at the 2026 American Academy of Neurology meeting. The trial met its primary endpoint, showing a 19% relative reduction in clinically significant hypotension with GTx-104 versus oral nimodipine, along with better dose intensity and functional outcomes.
Actionable Insight
GTx-104 continues to demonstrate clinical and delivery advantages over oral nimodipine. The upcoming AAN presentation may catalyze investor and KOL interest ahead of a potential NDA submission. Monitor for further regulatory updates and potential partnership interest.
Key Facts
- STRIVE-ON trial met primary endpoint: 28% of GTx-104 patients experienced clinically significant hypotension vs. 35% on oral nimodipine (19% relative reduction).
- 54% of GTx-104 patients achieved ≥95% relative dose intensity vs. 8% on oral nimodipine.
- 29% more patients on GTx-104 had favorable functional outcomes at 90 days compared to oral nimodipine.
- No new safety signals were identified; all deaths were attributed to underlying disease severity, not treatment.
- Data to be presented April 21, 2026, at AAN meeting, a key medical forum for neurology stakeholders.
Financial Impact
Potential for improved pharmacoeconomic profile with fewer ICU readmissions, ventilator days, and ICU days, though exact dollar impact not quantified.
Risk Factors
- Regulatory approval not guaranteed despite positive Phase 3 data.
- Higher mortality in GTx-104 arm (8 vs. 4 deaths) could raise questions, though deemed unrelated to treatment.
- Market cap remains small ($51M), making stock volatile to sentiment shifts.
Market Snapshot
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3273250 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 5, 2026
4d ago
|
8-K
| $2.38 awaiting T+20 | awaiting T+20 | — | $2.33 (−2.10%) |
|
Apr 27, 2026
6w ago
|
8-K
| $2.16 $2.36 | ▼ −9.26% | ▼ −4.30% | $2.33 (−7.87%) |
|
Apr 23, 2026
6w ago
|
8-K
| $2.35 $2.18 | ▲ +7.23% | ▲ +11.87% | $2.33 (+0.85%) |
|
Apr 14, 2026
8w ago
|
Press Release
| $4.28 $2.35 | ▼ −45.09% | ▼ −51.39% | $2.33 (−45.56%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access